Clinical Trial

Triple Therapy in T1DM

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-03-29; most recent amendment 2026-05-28.
Status change: Recruiting → Active, Not Recruiting 2025-03-31
Status change: Not Yet Recruiting → Recruiting 2019-10-01
Trial Details
NCT Number NCT03899402
Lead Sponsor State University of New York at Buffalo
Collaborators: University of Glasgow, Juvenile Diabetes Research Foundation
Conditions Type 1 Diabetes Mellitus
Enrollment 78 participants
Start Date 2019-05-01
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29